rHEALTH FVIII Solution to be Presented at WFH’s 11th Global Forum

We are very pleased to be invited by WFH to present our FVIII point-of-care solution for home and in-office measurement of FVIII levels,” said Eugene Y. Chan, MD. “Our approach delivers highly accurate FVIII measurements, particularly for long-acting and gene therapy-based treatments, where conventional testing via activated partial thromboplastin time is less reliable.”

The rHEALTH FVIII solution employs a patent-pending two-stage biochemistry to ensure precision even in the presence of interferents such as lupus anticoagulant, and enables early detection of inhibitors. This makes it uniquely suited for patients who otherwise lack access to specialized FVIII testing.

The WFH forum will be held at the Westin Hotel in Montreal, November 13–14, 2019, addressing issues related to the safety and supply of treatments for bleeding disorders. The event will bring together patient groups, regulators, industry representatives, not-for-profit fractionators, and clinicians treating people with bleeding disorders. Dr. Chan’s presentation is scheduled for November 13, 2019, at 3:00 PM EST.